Premium
Disposition of 5‐fluorouracil during chronic hepatic arterial infusion to patients with carcinoma in the liver and effect on circulating platelets
Author(s) -
Sitar Daniel S.,
Ruedy John R.,
Shaw Douglas H.,
Maksymiuk Andrew W.,
Thirlwell Michael P.
Publication year - 1979
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510010104
Subject(s) - platelet , fluorouracil , medicine , bolus (digestion) , toxicity , pharmacokinetics , pharmacology , gastrointestinal tract , hepatic arterial infusion , drug , urinary system , gastroenterology , cancer , colorectal cancer
5‐Fluorouracil was administered by continuous hepatic intra‐arterial infusion to eight patients with the diagnosis of cancer of the gastrointestinal tract and hepatic metastases. Its elimination characteristics were investigated to see if they correlated with therapeutic effect or reduced clinical toxicity when the drug was given by this route. Urinary excretion of drug and metabolites was similar to findings after intravenous bolus doses. Disposition changes could not be correlated with therapeutic effect or clinical toxicity. A dose‐related biphasic effect of 5‐fluorouracil was found on circulating platelets. Doses greater than 6 mg kg −1 d −1 decreased the number of circulating platelets, while doses less than that resulted in an increase in circulating platelets. Further studies are required to determine the mechanism of the effect of 5‐fluorouracil on platelets.